Specificity mechanism of Group VIA calcium-independent phospholipase A2 toward truncated-oxidized phospholipids and its application for specific inhibitor design
- PMID: 40592420
- PMCID: PMC12338845
- DOI: 10.1016/j.bbalip.2025.159655
Specificity mechanism of Group VIA calcium-independent phospholipase A2 toward truncated-oxidized phospholipids and its application for specific inhibitor design
Abstract
Phospholipase A2 (PLA2) constitutes a superfamily of enzymes that hydrolyze the sn-2 fatty acyl chain of glycerophospholipids. Polyunsaturated fatty acids (PUFAs) are preferentially attached at the sn-2 position of glycerophospholipids and are easily truncated by oxidation. The truncated-oxidized phospholipids (tr-oxPLs) trigger various cellular responses, and PLA2s may play a critical role in the metabolism of the tr-oxPLs by removing the oxidized sn-2 chain. In the present study, we demonstrated using an in vitro lipidomics assay that Group VIA calcium-independent PLA2 (GVIA iPLA2) showed high activity toward phosphatidylcholine with a 9-oxononanoyl chain, but not with an azelaoyl chain on the sn-2 position. We conducted molecular dynamics simulations which revealed that the hydrophilicity of the sn-2 acyl chain critically affects the binding of the substrate in the active site. Based on the unique specificity of GVIA iPLA2 toward tr-oxPLs, we synthesized an oxidatively modified inhibitor (GK766) for GVIA iPLA2, aiming for improvement of its selectivity and/or potency. As we expected, the modified inhibitor improved its selectivity of GVIA iPLA2 compared to the unmodified inhibitor (GK187), although the inhibitory effect became somewhat weaker. More importantly, we demonstrated that GK766 induces cell death by ferroptosis more effectively than GK187 using an erythroleukemia cell line. In the present study, we have further defined the unique substrate specificity of GVIA iPLA2 toward tr-oxPLs and its molecular mechanism. Furthermore, we have developed a novel specificity-based inhibitor that induces ferroptosis demonstrating that using substrate selectivity helps in developing more effective therapeutics.
Keywords: Ferroptosis; Inhibitor design; Oxidized phospholipids; PLA(2).
Copyright © 2025 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Molecular basis of unique specificity and regulation of group VIA calcium-independent phospholipase A2 (PNPLA9) and its role in neurodegenerative diseases.Pharmacol Ther. 2023 May;245:108395. doi: 10.1016/j.pharmthera.2023.108395. Epub 2023 Mar 27. Pharmacol Ther. 2023. PMID: 36990122 Free PMC article. Review.
-
Toward pharmacologic therapy for glioblastoma: Identifying inhibitors of very long-chain acyl-CoA synthetase 3 (ACSVL3).bioRxiv [Preprint]. 2025 Jul 3:2025.07.02.662811. doi: 10.1101/2025.07.02.662811. bioRxiv. 2025. PMID: 40631213 Free PMC article. Preprint.
-
How Membrane Phospholipids Containing Long-Chain Polyunsaturated Fatty Acids and Their Oxidation Products Orchestrate Lipid Raft Dynamics to Control Inflammation.J Nutr. 2024 Sep;154(9):2862-2870. doi: 10.1016/j.tjnut.2024.07.015. Epub 2024 Jul 25. J Nutr. 2024. PMID: 39025329 Free PMC article. Review.
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials